Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932449 · ClinicalTrials.gov registry record
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A clinical trial, sponsored by Target PharmaSolutions.
- Completed
- Registry status
- 711
- Enrollment target
NCT02932449: Completed study, sponsored by Target PharmaSolutions.
NCT02932449 is a clinical trial that has completed, run by Target PharmaSolutions. The registered enrollment target is 711 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02932449 has completed, sponsored by Target PharmaSolutions.
- COMPLETED
- Registry status
- 711 participants
- Enrollment target
Study Summary
This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2016-10 |
| Est. Completion | 2025-01-23 |
What the finished NCT02932449 record still lists
NCT02932449 is an observational study that tracks outcomes without assigning an intervention. The registered 711 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02932449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02932449 about?
NCT02932449 is a clinical study titled "A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis". This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational ...
What is the current status of trial NCT02932449?
This trial is currently completed. The enrollment target is 711 participants. The study started on 2016-10. Estimated completion is 2025-01-23.
Who is sponsoring clinical trial NCT02932449?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia